Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer
Primary Purpose
Breast Cancer, Locally Advanced Breast Cancer
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sentinel Lymph Node Biopsy (SLNB)
Sponsored by
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring Sentinel Lymph Node Biopsy, 17-384
Eligibility Criteria
Inclusion Criteria:
- Female patients over 18 years of age with biopsy-proven breast cancer
- Patients presenting with locally advanced disease in the breast (cT4) and/or in the nodes (cN2/N3) as assessed by clinical exam and imaging
- Patients presenting to surgery clinic after receipt of NAC at outside hospital with documentation of cT4 or cN2/3 disease on initial outside physical exam and imaging studies
- Patients receiving NAC and having a nodal complete clinical response as assessed by physical exam
Exclusion Criteria:
- Patients with a prior history of ipsilateral breast cancer
- Pregnant patients
- Patients with persistent palpable axillary nodes after NAC, as assessed by physical exam
- Patients not consenting to ALND
Sites / Locations
- BAPTIST ALLIANCE - MCI (Data Collection Only)Recruiting
- Memorial Sloan Kettering at Basking Ridge (Consent and Follow Up)Recruiting
- Memorial Sloan Kettering MonmouthRecruiting
- Memorial Sloan Kettering Bergen (Consent only and Follow Up)Recruiting
- Memorial Sloan Kettering CommackRecruiting
- Memorial Sloan Kettering WestchesterRecruiting
- Memorial Sloan Kettering Cancer CenterRecruiting
- Memorial Sloan Kettering Nassau (Consent only and Follow Up)Recruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Sentinel Lymph Node Biopsy (SLNB)
Arm Description
The patients will undergo SLNB with dual tracer mapping using technetium-99m sulfur colloid and isosulfan blue dye, as is standard practice at our institution for cN1 patients. Than the SLNB procedure will be performed
Outcomes
Primary Outcome Measures
The false negative rate of sentinel lymph node biopsy in patients with locally advanced breast cancer
Secondary Outcome Measures
Full Information
NCT ID
NCT03255577
First Posted
August 18, 2017
Last Updated
May 22, 2023
Sponsor
Memorial Sloan Kettering Cancer Center
1. Study Identification
Unique Protocol Identification Number
NCT03255577
Brief Title
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer
Official Title
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients Presenting With Locally Advanced Breast Cancer: A Prospective Study
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 17, 2017 (Actual)
Primary Completion Date
June 15, 2024 (Anticipated)
Study Completion Date
August 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Memorial Sloan Kettering Cancer Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This study is being done to help the investigators determine how accurate the sentinel lymph node biopsy (SLNB) procedure is in identifying residual cancer cells after neoadjuvant chemotherapy in patients presenting with locally advanced breast cancer.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer, Locally Advanced Breast Cancer
Keywords
Sentinel Lymph Node Biopsy, 17-384
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
This will be a prospective single-arm study design.
Masking
None (Open Label)
Allocation
N/A
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Sentinel Lymph Node Biopsy (SLNB)
Arm Type
Experimental
Arm Description
The patients will undergo SLNB with dual tracer mapping using technetium-99m sulfur colloid and isosulfan blue dye, as is standard practice at our institution for cN1 patients. Than the SLNB procedure will be performed
Intervention Type
Procedure
Intervention Name(s)
Sentinel Lymph Node Biopsy (SLNB)
Intervention Description
Sentinel Lymph Node Biopsy Patients with locally advanced breast cancer will undergo SLNB with dual tracer mapping followed by completion axillary lymph node dissection.
Primary Outcome Measure Information:
Title
The false negative rate of sentinel lymph node biopsy in patients with locally advanced breast cancer
Time Frame
3 years
10. Eligibility
Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female patients over 18 years of age with biopsy-proven breast cancer
Patients presenting with locally advanced disease in the breast (cT4) and/or in the nodes (cN2/N3) as assessed by clinical exam and imaging
Patients presenting to surgery clinic after receipt of NAC at outside hospital with documentation of cT4 or cN2/3 disease on initial outside physical exam and imaging studies
Patients receiving NAC and having a nodal complete clinical response as assessed by physical exam
Exclusion Criteria:
Patients with a prior history of ipsilateral breast cancer
Pregnant patients
Patients with persistent palpable axillary nodes after NAC, as assessed by physical exam
Patients not consenting to ALND
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andrea Barrio, MD
Phone
646-888-5117
Email
barrioa@mskcc.org
First Name & Middle Initial & Last Name or Official Title & Degree
Monica Morrow, MD
Phone
646-888-5350
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrea Barrio, MD
Organizational Affiliation
Memorial Sloan Kettering Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
BAPTIST ALLIANCE - MCI (Data Collection Only)
City
Miami
State/Province
Florida
ZIP/Postal Code
33143
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Starr Mautner, MD
Phone
786-596-2000
Facility Name
Memorial Sloan Kettering at Basking Ridge (Consent and Follow Up)
City
Basking Ridge
State/Province
New Jersey
ZIP/Postal Code
07920
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Barrio, MD
Phone
646-888-5117
Facility Name
Memorial Sloan Kettering Monmouth
City
Middletown
State/Province
New Jersey
ZIP/Postal Code
07748
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Barrio, MD
Phone
646-888-5117
Facility Name
Memorial Sloan Kettering Bergen (Consent only and Follow Up)
City
Montvale
State/Province
New Jersey
ZIP/Postal Code
07645
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Barrio, MD
Phone
646-888-5117
Facility Name
Memorial Sloan Kettering Commack
City
Commack
State/Province
New York
ZIP/Postal Code
11725
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Barrio, MD
Phone
646-888-5117
Facility Name
Memorial Sloan Kettering Westchester
City
Harrison
State/Province
New York
ZIP/Postal Code
10604
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Barrio, MD
Phone
646-888-5117
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Barrio, MD
Phone
646-888-5117
First Name & Middle Initial & Last Name & Degree
Monica Morrow, MD
Phone
646-888-5350
First Name & Middle Initial & Last Name & Degree
Andrea Barrio, MD
Facility Name
Memorial Sloan Kettering Nassau (Consent only and Follow Up)
City
Uniondale
State/Province
New York
ZIP/Postal Code
11553
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Barrio, MD
Phone
646-888-5117
12. IPD Sharing Statement
Links:
URL
http://www.mskcc.org/mskcc/html/44.cfm
Description
Memorial Sloan Kettering Cancer Center
Learn more about this trial
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer
We'll reach out to this number within 24 hrs